Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

VYNE Therapeutics Inc. Director's Dealing 2021

Aug 26, 2021

35290_dirs_2021-08-26_2dfa440c-7907-4462-84f4-2caae9d4a5fa.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VYNE Therapeutics Inc. (VYNE)
CIK: 0001566044
Period of Report: 2021-08-25

Reporting Person: LEPORE PATRICK G (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-08-25 Common Stock P 12500 $1.60 Acquired 50000 Direct

Footnotes

F1: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.59 to $1.60, inclusive. The reporting person undertakes to provide to VYNE Therapeutics Inc., any security holder of VYNE Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.